NPI: 1104182492 · HOLLYWOOD, FL 33020 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 04/11/2012
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 04/11/2012 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 4,829 | $257K |
| 2019 | 3,888 | $211K |
| 2020 | 6,593 | $585K |
| 2021 | 2,546 | $207K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 7,784 | 524 | $535K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 5,318 | 245 | $370K |
| A4657 | Syringe, with or without needle, each | 896 | 409 | $135K |
| J1270 | Injection, doxercalciferol, 1 mcg | 2,136 | 151 | $102K |
| 83550 | 394 | 305 | $26K | |
| 83540 | 395 | 305 | $26K | |
| 85041 | 304 | 224 | $19K | |
| 85048 | 276 | 208 | $19K | |
| 83970 | 165 | 128 | $12K | |
| 82728 | 124 | 89 | $11K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 48 | 13 | $3K |
| 82108 | 16 | 13 | $853.83 |